JP5886192B2 - 内在化ペプチド連結薬剤と抗炎症剤との共投与 - Google Patents

内在化ペプチド連結薬剤と抗炎症剤との共投与 Download PDF

Info

Publication number
JP5886192B2
JP5886192B2 JP2012515161A JP2012515161A JP5886192B2 JP 5886192 B2 JP5886192 B2 JP 5886192B2 JP 2012515161 A JP2012515161 A JP 2012515161A JP 2012515161 A JP2012515161 A JP 2012515161A JP 5886192 B2 JP5886192 B2 JP 5886192B2
Authority
JP
Japan
Prior art keywords
peptide
seq
pharmacological agent
tat
mast cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012515161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530060A (ja
JP2012530060A5 (enExample
Inventor
マイケル ティミアンスキ，
マイケル ティミアンスキ，
ジョナサン デイビッド ガーマン，
ジョナサン デイビッド ガーマン，
ホン チェ，
ホン チェ，
Original Assignee
ノノ インコーポレイテッド
ノノ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノノ インコーポレイテッド, ノノ インコーポレイテッド filed Critical ノノ インコーポレイテッド
Publication of JP2012530060A publication Critical patent/JP2012530060A/ja
Publication of JP2012530060A5 publication Critical patent/JP2012530060A5/ja
Application granted granted Critical
Publication of JP5886192B2 publication Critical patent/JP5886192B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2012515161A 2009-06-10 2010-06-10 内在化ペプチド連結薬剤と抗炎症剤との共投与 Expired - Fee Related JP5886192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18594309P 2009-06-10 2009-06-10
US61/185,943 2009-06-10
PCT/US2010/038226 WO2010144742A2 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134712A Division JP6238934B2 (ja) 2009-06-10 2015-07-03 内在化ペプチド連結薬剤と抗炎症剤との共投与

Publications (3)

Publication Number Publication Date
JP2012530060A JP2012530060A (ja) 2012-11-29
JP2012530060A5 JP2012530060A5 (enExample) 2013-07-04
JP5886192B2 true JP5886192B2 (ja) 2016-03-16

Family

ID=43309471

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012515161A Expired - Fee Related JP5886192B2 (ja) 2009-06-10 2010-06-10 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2015134712A Expired - Fee Related JP6238934B2 (ja) 2009-06-10 2015-07-03 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2017179192A Expired - Fee Related JP6775478B2 (ja) 2009-06-10 2017-09-19 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2020074428A Active JP7209364B2 (ja) 2009-06-10 2020-04-17 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2022170797A Pending JP2023017813A (ja) 2009-06-10 2022-10-25 内在化ペプチド連結薬剤と抗炎症剤との共投与

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015134712A Expired - Fee Related JP6238934B2 (ja) 2009-06-10 2015-07-03 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2017179192A Expired - Fee Related JP6775478B2 (ja) 2009-06-10 2017-09-19 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2020074428A Active JP7209364B2 (ja) 2009-06-10 2020-04-17 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2022170797A Pending JP2023017813A (ja) 2009-06-10 2022-10-25 内在化ペプチド連結薬剤と抗炎症剤との共投与

Country Status (16)

Country Link
US (4) US8933013B2 (enExample)
EP (2) EP3682895A1 (enExample)
JP (5) JP5886192B2 (enExample)
AU (1) AU2010259986B2 (enExample)
CA (2) CA2765171C (enExample)
CY (1) CY1122584T1 (enExample)
DK (1) DK2440231T3 (enExample)
ES (1) ES2765281T3 (enExample)
HR (1) HRP20192230T1 (enExample)
HU (1) HUE046640T2 (enExample)
LT (1) LT2440231T (enExample)
PL (1) PL2440231T3 (enExample)
PT (1) PT2440231T (enExample)
SI (1) SI2440231T1 (enExample)
SM (1) SMT202000056T1 (enExample)
WO (1) WO2010144742A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2320927T3 (pl) * 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
PT2440231T (pt) * 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
TR201905787T4 (tr) * 2012-11-28 2019-05-21 Nono Inc Liyofilize TAT-NR2B9C formülasyonu.
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
WO2017115853A1 (ja) 2015-12-28 2017-07-06 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN111417394B (zh) 2017-10-19 2023-11-07 帝人制药株式会社 苯并咪唑衍生物及其用途
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
EP4274596A4 (en) 2021-01-08 2024-12-25 NoNO Inc. Plasmin-resistant peptides for improved therapeutic index

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
CA2354644A1 (en) 1998-12-11 2000-06-15 Biomira, Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
WO2003024389A2 (en) 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
CA2505479A1 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
KR101384572B1 (ko) 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
CA2657665C (en) * 2006-07-11 2015-06-02 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
DK2178549T3 (en) 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
ES2328776B1 (es) 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
PT2440231T (pt) 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos

Also Published As

Publication number Publication date
SMT202000056T1 (it) 2020-03-13
JP2020125328A (ja) 2020-08-20
EP2440231A4 (en) 2013-04-24
AU2010259986B2 (en) 2015-04-02
US9433685B2 (en) 2016-09-06
SI2440231T1 (sl) 2020-08-31
US8933013B2 (en) 2015-01-13
US20150126460A1 (en) 2015-05-07
JP6238934B2 (ja) 2017-11-29
CA3018494C (en) 2021-12-07
EP2440231A2 (en) 2012-04-18
WO2010144742A3 (en) 2011-04-21
DK2440231T3 (da) 2020-01-13
JP2012530060A (ja) 2012-11-29
JP2016000735A (ja) 2016-01-07
US20120252731A1 (en) 2012-10-04
HRP20192230T1 (hr) 2020-03-20
CA2765171C (en) 2018-10-02
JP6775478B2 (ja) 2020-10-28
PL2440231T3 (pl) 2020-05-18
EP2440231B1 (en) 2019-12-04
CA3018494A1 (en) 2010-12-16
US10046060B2 (en) 2018-08-14
ES2765281T3 (es) 2020-06-08
AU2010259986A1 (en) 2012-01-12
EP3682895A1 (en) 2020-07-22
JP2023017813A (ja) 2023-02-07
CA2765171A1 (en) 2010-12-16
JP2018030859A (ja) 2018-03-01
WO2010144742A2 (en) 2010-12-16
US20190038760A1 (en) 2019-02-07
PT2440231T (pt) 2020-01-08
US20170043030A1 (en) 2017-02-16
CY1122584T1 (el) 2021-01-27
HUE046640T2 (hu) 2020-03-30
LT2440231T (lt) 2020-01-10
JP7209364B2 (ja) 2023-01-20

Similar Documents

Publication Publication Date Title
JP6238934B2 (ja) 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP5520230B2 (ja) 内在化ペプチドに連結された薬剤と抗炎症剤との共投与
JP6741642B2 (ja) くも膜下出血および虚血の治療法
JP2024502463A (ja) 治療指数を改善するためのプラスミン耐性ペプチド
JP2023511057A (ja) 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
CN116897051A (zh) 用于提高治疗指数的抗纤溶酶肽

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160210

R150 Certificate of patent or registration of utility model

Ref document number: 5886192

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees